---
title: "Opdivo (nivolumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Opdivo (nivolumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Opdivo work (mechanism of action)? How long does Opdivo stay in your system (half-life)? What are the inactive ingredients in Opdivo and Opdivo Qvantig? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab), all indications: Pharmacology questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)  
Indication pages: [Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)

## Mechanism

<a id="opdivo-mechanism"></a>

### How does Opdivo work (mechanism of action)?

> “OPDIVO helps existing T cells discover the tumor by blocking PD-1, an immune checkpoint. This process may also target normal cells.<sup>10-12</sup>”

Source: [OPDIVO: Mechanism of Disease & Mechanism of Action, captured 2026-11-13](https://www.opdivohcp.com/moa#:~:text=OPDIVO%20helps%20existing%20T%20cells,process%20may%20also%20target%20normal)

This passage is in a collapsed section of the page; select: 2L METASTATIC NSCLC OPDIVO

> “Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell 
> proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and 
> signaling through this pathway can contribute to inhibition of active T-cell immune surveillance 
> of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds 
> to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-
> mediated inhibition of the immune response, including the anti-tumor immune response. 
> In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

## Pharmacokinetics

<a id="opdivo-half-life"></a>

### How long does Opdivo stay in your system (half-life)?

> “The geometric mean elimination half-life (t1/2) is 25 days (77.5%).”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

> “Steady-state concentrations of nivolumab 
> were reached by 12 weeks when administered at 3 mg/kg every 2 weeks, and systemic 
> accumulation was 3.7-fold.”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

> “The elimination half-life is 25 days (78%).”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

Note: The first two passages are from the Opdivo (intravenous) Prescribing Information and the third from the Opdivo Qvantig Prescribing Information.

## Components

<a id="opdivo-inactive-ingredients"></a>

### What are the inactive ingredients in Opdivo and Opdivo Qvantig?

> “OPDIVO (nivolumab) injection for intravenous use is supplied in single-dose vials. Each mL 
> of OPDIVO solution contains nivolumab (10 mg), mannitol (30 mg), pentetic acid (0.008 mg), 
> polysorbate 80 (0.2 mg), sodium chloride (2.92 mg), sodium citrate dihydrate (5.88 mg), and 
> Water for Injection, USP. May contain hydrochloric acid and/or sodium hydroxide to adjust pH to 6.”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

> “Each 2.5 mL single-dose vial contains 300 mg of nivolumab and 5,000 units of 
> hyaluronidase (human recombinant), and the inactive ingredients: histidine (3.88 mg), histidine 
> hydrochloride monohydrate (5.25 mg), methionine (1.87 mg), pentetic acid (0.049 mg), 
> polysorbate 80 (1.25 mg), sucrose (214 mg), and Water for Injection, USP. The pH is 5.5 to 6.5.”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

> “Each 5 mL single-dose vial contains 600 mg of nivolumab and 10,000 units of hyaluronidase 
> (human recombinant), and the inactive ingredients: histidine (7.75 mg), histidine hydrochloride 
> monohydrate (10.5 mg), methionine (3.73 mg), pentetic acid (0.0985 mg), polysorbate 80 
> (2.5 mg), sucrose (428 mg), and Water for Injection, USP. The pH is 5.5 to 6.5.”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

## Related pages
- [Medical information: Opdivo (nivolumab): All indications](https://www.evicenter.com/medical-information/opdivo)
- [Indication](https://www.evicenter.com/medical-information/opdivo/indication)
- [Safety](https://www.evicenter.com/medical-information/opdivo/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo/storage-and-supply)
